TML/BSE/NSE/2026-27/17 13th August 2026

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 530199

Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: THEMISMED

Dear Sir / Madam,

Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Thursday, 13th August, 2026, have transacted the following business:

1. Considered and approved the Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 together with the Limited Review Reports of the Statutory Auditors, M/s. Krishaan & Co., Chartered Accountants which are attached herewith.

2. Noted & approved the resignation of Mr. Nagraj Mogaveera as Interim Company Secretary & Compliance Officer of the Company w.e.f. 13th August, 2026. (Details mentioned in the attached Annexure A).

3. Considered and approved the appointment of Mr. Suresh Savaliya as Company Secretary, Compliance Officer & Key Managerial Personnel (KMP) of the Company in place of Mr. Nagraj Mogaveera w.e.f. 13th August, 2026. (Details mentioned in the attached Annexure B).

The Board meeting commenced at 10.30 A.M (IST) and concluded at 12.45 P.M (IST).

Submitted for your information & record please.

Thanking you,

Yours faithfully,

For **THEMIS MEDICARE LIMITED**

Dinesh Shantilal Patel
Digitally signed by Dinesh Shantilal Patel
Date: 2026.08.13 12:47:49 +05'30'

Dr. Dinesh S. Patel
Director

ANNEXURE A

Sr. No	Particulars	Details
1.	Reason for change- resignation	Resignation: Mr. Nagraj Mogaveera has tendered his resignation from the position of Interim Company Secretary, Compliance Officer & KMP due to transitioning into a different role within the Company as Deputy Manager – Secretarial Department with effect from 13th August, 2026.
2.	Date of Resignation	13th August, 2026
3.	Brief Profile (in case of appointment)	Not Applicable
4.	Disclosure of relationship between Directors (in case of appointment)	Not Applicable

Annexure B

Sr. No	Particulars	Details
1.	Reason for change-Appointment.	Appointment: The Board of Directors have approved the appointment of Mr. Suresh Savaliya as the Company Secretary, Compliance Officer and Key Managerial Personnel (KMP) of the Company with effect from 13th August, 2026.
2.	Date of Appointment	13th August, 2026
3.	Brief Profile (in case of appointment)	Mr. Suresh Savaliya is a Qualified Company Secretary and a Member of the Institute of Company Secretaries of India (ICSI), with post qualification experience of 23 years in Company Secretarial, Corporate Governance, Compliances including listed company compliances, SEBI Regulations & other Company Secretarial matters. He has previously worked with Reliance Industries Limited, Essel Group and other leading corporates, where he has handled Company Secretarial functions, SEBI and stock exchange compliances, Board and Committee matters, corporate governance, and various regulatory and statutory compliances.
4.	Disclosure of relationship between Directors (in case of appointment)	Not Applicable

THEMIS MEDICARE LTD
CIN NO : L24110GJ1969PLC001590
Regd. Off. Plot No. 69-A, GIDC Indl, Estate, Vapi - 396195, Dist Valsad,
Gujarat. (T) 0260-2431447 / 0260-2430219,
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104,
Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Standalone Financial Results for the quarter ended 30th June 2026

(Amount in INR Lakhs)

	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year Ended
		30/06/2026	**31/03/2026**	**30/06/2025**	**31/03/2026**
		(Unaudited)	**(Audited)**	**(Unaudited)**	**(Audited)**
	Income:				
1	Revenue from Operations (Net)	8,695.69	7,653.05	9,757.77	34,223.55
2	Other income	99.37	366.70	117.59	936.16
3	**Total Income (1+2)**	**8,795.06**	**8,019.75**	**9,875.36**	**35,159.71**
4	**Expenses:**				
	(a)Cost of materials consumed	1,763.42	1,426.99	1,242.99	5,730.34
	(b)Purchases of Stock-in-Trade	4,981.01	1,146.36	2,167.58	6,300.24
	(c)Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(945.80)	(198.35)	1,829.27	916.54
	(d) Employee benefits expense	2,218.23	2,106.01	2,484.91	9,351.68
	(e) Finance costs	297.74	270.38	247.02	1,068.86
	(f) Depreciation and amortization expense	254.21	260.08	255.28	1,032.11
	(g) Other expenses	5,920.71	2,794.70	3,040.77	11,884.12
	Total Expenses (II)	**14,489.52**	**7,806.17**	**11,267.82**	**36,283.89**
5	**Profit/(loss) before exceptional items and tax (3-4)**	**(5,694.46)**	**213.58**	**(1,392.46)**	**(1,124.18)**
6	**Exceptional items [net] :**				
	Impact of Labour Codes (Refer Note No. 4 (i))	-	-	-	(86.53)
	Investments in wholly owned Subsidiary Company w/off (Refer Note No. 4(ii))	-	-	(129.39)	(129.39)
	Profit on sale of shares (Refer Note No. 4 (iii))	9,966.79	-	-	-
7	**Profit/(Loss) before tax (5+6)**	**4,272.33**	**213.58**	**(1,521.85)**	**(1,340.10)**
8	**Tax expense:**				
	(a) Current Tax	825.00	-	-	-
	(b) Deferred Tax	573.61	17.02	15.52	78.45
9	**Profit/ (Loss) for the Period (7-8)**	**2,873.72**	**196.56**	**(1,537.37)**	**(1,418.55)**
10	**Other Comprehensive Income**				
	(a i) Items that will not be reclassified to profit & loss	(24.56)	(8.18)	(10.33)	(98.24)
	(a ii) Income tax relating to items that will not be reclassified to profit or loss	6.18	2.05	2.60	24.72
	(b) Items that will be reclassified to profit & loss	-	-	-	-
11	**Total comprehensive income for the period (9+10)**	**2,855.34**	**190.43**	**(1,545.10)**	**(1,492.07)**
12	Paid up Equity Share Capital (Face Value of Rs.1/- per Equity Share)	921.00	921.00	920.40	921.00
13	Other Equity (Excluding Revaluation Reserve)				25,916.47
	Earnings per share (EPS) (of Rs. 1 each)				
	(a) Basic	3.12	0.21	(1.67)	(1.54)
	(b) Diluted	3.12	0.21	(1.67)	(1.54)

THEMIS MEDICARE LTD. MUMBAI

THEMIS MEDICARE LIMITED

NOTES :

1) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its respective meeting held on August 13, 2026.

2) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act , 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.

3) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable business segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".

4) **(i)** On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employement published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the best information available and consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the regulatory-driven and non-recurring nature of this impact, the Company has presented such incremental impact under Exceptional Items amounting to Rs. 86.53 lacs in the standalone financial results for the quarter and period ended December 31, 2025. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

(ii) The company has received an approval for struck off M/s. Carpo Medicals Limited (UK), a wholly owned subsidiary company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. Accordingly, the company has provided for Investment Rs. 0.76 lacs and Receivable and advances amounting to Rs. 128.63 Lacs in the Financial Statement as the Company is in the process of obtaining approval from the Reserve Bank of India (RBI) under the Foreign Exchange Management Act (FEMA), 1999, for writing off the said investments. The company has disclosed the Investments, receivables and advances provided for, as an exceptional item in the Statement of Profit and Loss in accordance with Ind AS 1 and applicable accounting principles. Subject to approvals from RBI for striking off the said foreign subsidiary, as per the provisions of the FEMA and applicable ODI regulations, the amounts will be written-off.

(iii) Subsequent to the approval of the Board of Directors on 13th February 2026 and Shareholders on 27 March 2026, the Company has sold 2497190 equity shares out of its investment in Gujarat Themis Biosyn Limited, an Associate Company, during the quarter ended June 30, 2026 for a consideration of Rs. 100 Cr. The profit on the sale of such investment amounting to Rs. 99.67 cr. has been included under Exceptional Items.

5) The figures of the quarter ended March 31, 2026 of the previous financial year is balancing figures between audited figures of the full financial year and published year-to-date figures for the nine months ended December 31, 2025.

6) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL
(Managing Director & CEO)
(DIN No. 00033353)

Place : Mumbai
Date : 13th August, 2026

KRISHAAN & CO.,
CHARTERED ACCOUNTANTS

FLAT NO. 10, 'C' WING
6TH FLOOR, PARSN MANERE
442 ANNA SALAI
CHENNAI 600 006
PH: +91-44-28272569
KSR@KRISHAAN.IN

INDEPENDENT AUDITORS' REVIEW REPORT ON THE UNAUDITED STANDALONE QUARTERLY AND YEAR –TO-DATE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS), REGULATIONS, 2015, AS AMENDED

Review Report to
The Board of Directors
THEMIS MEDICARE LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of THEMIS MEDICARE LIMITED ("the Company") for the quarter ended 30th June 2026 ("the Statement") and being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended (the "Listing Regulations").

2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the company at their meeting held on 13th August 2026 and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IndAS 34") prescribed under Section 133 of the Companies Act 2013 and other Accounting Principles generally accepted in India and in compliance with Regulation 33 of Listing Regulations. Our responsibility is to issue a report on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying the analytical and other review procedures and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

KRISHAAN & CO. CHENNAI CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies thereon, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Krishaan & Co.,
Firm Reg. No.001453S
Chartered Accountants

K Sundarrajan
Partner
Membership No. 208431
UDIN: 26208431VGGQSB6782

KRISHAAN & CO., CHENNAI, CHARTERED ACCOUNTANTS

Date : 13th August 2026
Place: Mumbai

THEMIS MEDICARE LTD
CIN NO : L24110GJ1969PLC001590
Regd. Off. Plot No. 69-A, GIDC Indl, Estate, Vapi - 396195, Dist Valsad,
Gujarat. (T) 0260-2431447 / 0260-2430219,
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104,
Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Consolidated Financial Results for the quarter ended 30th June 2026

	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income:				
1	Revenue from Operations (Net)	8,695.69	7,653.05	9,757.77	34,223.55
2	Other income	99.37	366.70	117.59	936.16
3	**Total Income (1+2)**	**8,795.06**	**8,019.75**	**9,875.36**	**35,159.71**
4	**Expenses:**				
	(a)Cost of materials consumed	1,763.42	1,426.99	1,242.99	5,730.34
	(b)Purchases of Stock-in-Trade	4,981.01	1,146.36	2,167.58	6,300.24
	(c)Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(945.80)	(198.35)	1,829.27	916.54
	(d) Employee benefits expense	2,218.23	2,106.01	2,484.91	9,351.68
	(e) Finance costs	297.74	270.38	247.02	1,068.86
	(f) Depreciation and amortization expense	254.21	260.08	255.28	1,032.11
	(g) Other expenses	5,920.88	2,795.59	3,041.19	11,885.43
	Total Expenses (II)	**14,489.69**	**7,807.06**	**11,268.24**	**36,285.20**
5	**Profit/ (Loss) before exceptional items, share of Profit/(Loss) of associates and joint venture and tax (3-4)**	**(5,694.63)**	**212.69**	**(1,392.88)**	**(1,125.49)**
6	**Exceptional item [net] :**				
	Impact of Labour Codes (Refer Note No. 4 (i))	-	-	-	(86.53)
	Profit on sale of shares (Refer Note No. 4 (ii))	9,295.34	-	-	-
7	Profit/ (Loss) before share of Profit/ (Loss) of associates and joint venture and tax **(5+6)**	**3,600.71**	**212.69**	**(1,392.88)**	**(1,212.02)**
8	Add: Share of Profit/ (Loss) of associates and a joint venture for the Period	259.04	692.87	(13.57)	1,404.84
9	**Profit/ (Loss) before tax (7 + 8)**	**3,859.75**	**905.56**	**(1,406.45)**	**192.82**
10	Tax expense:				
	(a) Current Tax	825.00	-	-	-
	(b) Deferred Tax	573.61	17.02	15.52	78.45
11	**Profit/ (Loss) for the Period (9-10)**	**2,461.14**	**888.54**	**(1,421.97)**	**114.37**
	Attributable to :				
	Equity holders of the Parent	2,461.14	888.55	(1,421.96)	114.39
	Non - Controlling interests	-	(0.01)	(0.01)	(0.02)
12	**Other Comprehensive Income**				
	(a i) Items that will not be reclassified to profit & loss	(24.56)	(8.18)	(10.33)	(98.24)
	(a ii) Income tax relating to items that will not be reclassified to profit or loss	6.18	2.05	2.60	24.72
	(a iii) Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method	0.03	0.10	0.29	0.12
	(b) Items that will be reclassified to profit & loss	-	-	4.64	4.65
13	**Total comprehensive income for the period (11+12)**	**2,442.79**	**882.51**	**(1,424.77)**	**45.62**
	Attributable to :				
	Equity holders of the Parent	2,442.79	882.52	(1,424.76)	45.64
	Non - Controlling interests	-	(0.01)	(0.01)	(0.02)
14	Paid up Equity Share Capital (Face Value of Rs.1/- per Equity Share)	921.00	921.00	920.40	921.00
15	Other Equity (Excluding Revaluation Reserve)				35,680.28
16	**Earnings per share (EPS) (of Rs. 1 each)**				
	(a) Basic	2.67	0.96	(1.54)	0.12
	(b) Diluted	2.67	0.96	(1.54)	0.12

THEMIS MEDICARE LTD. MUMBAI

THEMIS MEDICARE LIMITED

NOTES :

1) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its respective meeting held on August 13, 2026.

2) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act , 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.

3) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".

4) **(i)** On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employement published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the best information available and consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the regulatory-driven and non-recurring nature of this impact, the Company has presented such incremental impact under Exceptional Items amounting to Rs. 86.53 lacs in the consolidated financial results for the quarter and period ended December 31, 2025. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

(ii) Subsequent to the approval of the Board of Directors on 13th February 2026 and Shareholders on 27 March 2026, the Company has sold 2497190 equity shares out of its investment in Gujarat Themis Biosyn Limited, an Associate Company, during the quarter ended June 30, 2026 for a consideration of Rs. 100 Cr. The profit on the sale of such investment amounting to Rs. 92.95 cr. has been included under Exceptional Items.

5) The figures of the quarter ended March 31, 2026 of the previous financial year is balancing figures between audited figures of the full financial year and published year-to-date figures for the nine months ended December 31, 2025.

6) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board
For THEMIS MEDICARE LTD





Dr. SACHIN PATEL
(Managing Director & CEO)
(DIN No. 00033353)

Place : Mumbai
Date : 13th August, 2026

KRISHAAN & CO.,
CHARTERED ACCOUNTANTS

FLAT NO. 10, 'C' WING
6TH FLOOR, PARSN MANERE
442 ANNA SALAI
CHENNAI 600 006
PH: +91-44-28272569
KSR@KRISHAAN.IN

INDEPENDENT AUDITORS' REVIEW REPORT ON THE UNAUDITED CONSOLIDATED QUARTERLY AND YEAR –TO-DATE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS), REGULATIONS, 2015, AS AMENDED

Review Report to
The Board of Directors
THEMIS MEDICARE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of THEMIS MEDICARE LIMITED ("the Parent"), its subsidiaries (the Parent and its subsidiaries together referred to as ("the Group"), and its share of the net profit after tax and total comprehensive income of its associates for the quarter ended 30th June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations and which has been initialled by us for identification purposes. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would

KRISHAAN & CO. CHENNAI CHARTERED ACCOUNTANTS

become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We have also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Subsidiaries

a) Themis Chemicals Private Limited
b) Artemis biotech Limited
c) Dr. Themis Private Limited

Associates

a) Gujarat Themis Biosyn Limited
b) Long Island Nutritionals Private Limited

Associate (Joint Venture)

a) Richter Themis Medicare (India) Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 3 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs.9.30 lakhs as at 30th June 2026 and total revenues of Rs.Nil, total net loss after tax of Rs.0.18 lakhs and total comprehensive income of Rs.NIL, for the quarter ended 30th June 2026. The consolidated

KRISHAAN & CO. CHENNAI CHARTERED ACCOUNTANTS

unaudited financial results also includes 2 Associates and 1 Joint Venture, whose interim financial information reflects total assets of Rs. 68,581.55 lakhs as at 30th June 2026 and total revenues of Rs. 7,208.04 lakhs, total net profit after tax of Rs. 1,163.26 lakhs and total comprehensive income of Rs. 0.13 lakhs for the quarter ended 30th June 2026. These financial information have been reviewed by other auditor's whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, are based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of the above matter.

7. We draw attention to Note No. 4(ii) of the Standalone Financial Statements, which indicates that during the previous year, the Company has provided for Investments amounting to Rs. 0.76 lacs in wholly-owned Subsidiary Company and Receivables and Advances amounting to Rs. 128.63 lacs due from its wholly-owned subsidiary, M/s. Carpo Medicals Limited (UK), on account of approval of Strike Off of the Company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. The Company is in the process of obtaining approval from the Reserve Bank of India under the Foreign Exchange Management Act, 1999 for writing off of the said investment.

Our conclusion on the Statement is not modified in respect of the above matter

For Krishaan & Co.,
Firm Reg. No.001453S
Chartered Accountants

K Sundarrajan
Partner
Membership No. 208431
UDIN: 26208431DRNYBT1891

Date : 13th August 2026
Place: Mumbai